Dose-escalation, Phase I Multicentric Trial, Evaluating the Combination of Ribociclib and Capecitabine in Locally Advanced or Metastatic Breast Cancer HER2 Negative in Patients Previously Treated With Anthracyclines and Taxanes
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2017
At a glance
- Drugs Capecitabine (Primary) ; Ribociclib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Acronyms GEP14-LEECAP
- 07 Jun 2017 Biomarkers information updated
- 09 Feb 2017 Status changed from not yet recruiting to recruiting.
- 09 Dec 2016 Planned initiation date changed from 1 Apr 2016 to 1 Jan 2017.